input_general_1 = '''
INCLUDE Participants must have a life expectancy of at least 3 months at the time of the first dose.
INCLUDE Are at least 18 years old.
INCLUDE Has an ECOG performance status of 0 or 1
'''

input_bodily_function_1 = '''
EXCLUDE Resting heart rate > 100 bpm
'''

input_infection_1 = '''
EXCLUDE Known HIV, active Hepatitis B without receiving antiviral treatment, or Hepatitis C; patients treated for Hepatitis C and have undetectable viral loads are eligible.
'''

input_reproduction_1 = '''
EXCLUDE Are pregnant.
'''

input_reproduction_2 = '''
INCLUDE Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to CNA3103 administration
'''

input_labvalue_1 = '''
INCLUDE ALT =< 135 U/L (must be performed within 7 days prior to enrollment). For the purpose of this study, the ULN for ALT is 45 U/L
'''

input_labvalue_2 = '''
INCLUDE Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements within 30 days before the start of study intervention:
    - Hemoglobin ≥9.0 g/dL.
    - Absolute neutrophil count (ANC) ≥1500/mm^3.
    - Platelet count ≥100,000/mm^3.
    - Total bilirubin ≤1.5 x ULN, or ≤3 x ULN if the participant has a confirmed history of Gilbert's syndrome.
    - ALT and AST <2.5 x ULN (≤5 x ULN for participants with liver involvement).
    - eGFR >60 mL/min/1.73 m^2, according to the MDRD abbreviated formula and creatinine clearance (CrCl) >60 mL/min based on Cockcroft-Gault formula.
'''

input_labvalue_3 = '''
INCLUDE Has adequate organ and bone marrow function as defined in the protocol
'''

input_cancer_type_1 = '''
INCLUDE Histologically or cytologically confirmed metastatic CRPC
INCLUDE Have a histopathologically confirmed diagnosis consistent with locally advanced unresectable or metastatic cholangiocarcinoma
'''

input_cancer_type_2 = '''
INCLUDE Histologically confirmed diagnosis of metastatic prostate cancer
INCLUDE Histologically or cytologically confirmed metastatic uveal melanoma
'''

input_cancer_type_3 = '''
EXCLUDE Participants who have any untreated symptomatic CNS metastases.
INCLUDE Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site
'''

input_cancer_type_4 = '''
INCLUDE Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
'''

input_second_malignancy_1 = '''
EXCLUDE Has second malignancy that is progressing or requires active treatment as defined in the protocol
'''

input_treatment_1 = '''
INCLUDE Is anti-PD-1/PD-L1 naïve, defined as never having previously been treated with a drug that targets the PD-1
'''

input_treatment_2 = '''
EXCLUDE Is currently participating in another study of a therapeutic agent
'''

input_toxicity_1 = '''
INCLUDE Any abnormalities in magnesium are not > Grade 2
'''

input_washout_period_1 = '''
EXCLUDE Has received recent anti-EGFR antibody therapy as defined in the protocol
'''
